

Amendments to the Specification:

Please insert the Sequence Listing being filed concurrently herewith into the specification.

Please amend paragraph [0162] on page 53 as follows:

[0162] Results and Discussion: The concentration of substrate converted to product was plotted as a function of time. The initial cleavage rate (V_o) was obtained from the slope (pM converted substrate per minute) of the best-fit line derived from ≥ 5 data points within the linear portion ($< 10\%$ of the total reaction) of the plot. The errors reported were based on three trials and is shown in the table below:

Sample	V_o (pM/min)	P	Sequence
2302	4.48 ± 0.81	-	5'-GCCCAAGCTGGCATCCGTCA (SEQ ID NO.: 1)
2302-TPT	25.91 ± 3.30	0.001	5'-GCCCAAGCTGGCATCCGTC-PSO ₂ (SEQ ID NO.: 2)

Analysis of the above table shows that the 3'-TPT species behaves better than the parent drug ($V_o = 25.91 \pm 3.30$) and is approximately six times more potent ($P = 0.001$) than SEQ ID NO:1.

Please amend Table 3 on page 56 as follows:

Table 3

5'-thiophosphate RNA 2'-O-methyl hemimers targeted to siRNA mediated PTEN message

SEQ ID NO	Sequence 5'-3'
10	5' O ₂ P(S)-O-UoUoUo GoUoCo UoCoUo GoGo Uo CoCoU*o U*oA*oC*o U*oU* 3'
11	5' O ₂ P(S)-O-AoAoAo CoAoGo AoGoAo CoCo Ao GoGoAo A*oU*oG*o A*oA* 3'
12	5' O ₂ P(S)-O-UsUsUs GsUsCs UsCsUs GsGsUs CsCsUs U*sA*sC*s U*sU* 3'

U* = 2'-O-methyluridine, A* = 2'-O-methyladenosine, C* = 2'-O-methylcytidine, G* = 2'-O-methylguanosine, o = PO, s = PS

Please amend Table 8 on pages 60-61 as follows:

Table 8

5'-dDoxy-5'-Thiophosphoricacid RNA 2'-O-methyl hemimers targeted to siRNA mediated PTEN message

SEQ ID NO	Sequence 5'-3'
25	5' O ₂ P(O)-S-UoUoUo GoUoCo UoCoUo GoGo Uo CoCoU*o U*oA*oC*o U*oU* 3'
26	5' O ₂ P(O)-S-AoAoAo CoAoGo AoGoAo CoCo Ao GoGoAo A*oU*oG*o A*oA* 3'
27	5' O ₂ P(O)-S-UsUsUs GsUsCs UsCsUs GsGsUs CsCsUs U*sA*sC*s U*sU* 3'

U* = 2'-O-methyluridine, A* = 2'-O-methyladenosine, C* = 2'-O-methylcytidine, G* = 2'-O-methylguanosine, o =PO, s = PS

Please amend Table 13 on page 65 as follows:

Table 13

5'-deoxy-5'-dithiophosphoricacid RNA 2'-O-methyl hemimers targeted to siRNA mediated PTEN message

SEQ ID NO	Sequence 5'-3'
40	5' O ₂ P(S)-S-UoUoUo GoUoCo UoCoUo GoGo Uo CoCoU*o U*oA*oC*o U*oU* 3'
41	5' O ₂ P(S)-S-AoAoAo CoAoGo AoGoAo CoCo Ao GoGoAo A*oU*oG*o A*oA* 3'
42	5' O ₂ P(S)-S-UsUsUs GsUsCs UsCsUs GsGsUs CsCsUs U*sA*sC*s U*sU* 3'

U* = 2'-O-methyluridine, A* = 2'-O-methyladenosine, C* = 2'-O-methylcytidine, G* = 2'-O-methylguanosine, o =PO, s = PS

Please amend the last paragraph on page 73 as follows:

For example, a duplex comprising an antisense strand having the sequence CGAGAGGCGGACGGGACCG (SEQ ID NO.: 64) and having a two-nucleobase overhang of deoxythymidine(dT) would have the following structure:

SEQ ID NO.

<u>65</u>	cgagaggcggacgggaccgTT	Antisense
	Strand	
<u>66</u>	TTgctctccgcctgccctggc	Complement